Use of AT-1 receptor antagonist or AT2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors

Details for Australian Patent Application No. 2006203077 (hide)

Owner Novartis AG

Inventors Bullock, Gillian Rosemary; De Gasparo, Marc; Ganter, Sabina Maria

Agent Davies Collison Cave

Pub. Number AU-B-2006203077

Parent 2003266433

Filing date 18 July 2006

Wipo publication date 10 August 2006

Acceptance publication date 8 October 2009

International Classifications

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 31/415 (2006.01) - 1,2-Diazoles

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/455 (2006.01) - Nicotinic acid, i.e. niacin

A61K 47/38 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Cellulose

Event Publications

3 August 2006 Complete Application Filed

10 August 2006 Application Open to Public Inspection

  Published as AU-B-2006203077

8 October 2009 Application Accepted

  Published as AU-B-2006203077

4 February 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006203078-Setting tool

2006203076-Lighter having safety device